GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Kaibao Pharmaceutical Co Ltd (SZSE:300039) » Definitions » Capex-to-Revenue

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Capex-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Shanghai Kaibao Pharmaceutical Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Shanghai Kaibao Pharmaceutical Co's Capital Expenditure for the three months ended in Mar. 2024 was ¥-0.96 Mil. Its Revenue for the three months ended in Mar. 2024 was ¥475.50 Mil.

Hence, Shanghai Kaibao Pharmaceutical Co's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.00.


Shanghai Kaibao Pharmaceutical Co Capex-to-Revenue Historical Data

The historical data trend for Shanghai Kaibao Pharmaceutical Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Kaibao Pharmaceutical Co Capex-to-Revenue Chart

Shanghai Kaibao Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.02 0.04 0.03 0.02

Shanghai Kaibao Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.03 0.01 0.03 -

Competitive Comparison of Shanghai Kaibao Pharmaceutical Co's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Kaibao Pharmaceutical Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Kaibao Pharmaceutical Co's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Kaibao Pharmaceutical Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shanghai Kaibao Pharmaceutical Co's Capex-to-Revenue falls into.



Shanghai Kaibao Pharmaceutical Co Capex-to-Revenue Calculation

Shanghai Kaibao Pharmaceutical Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-29.076) / 1594.051
=0.02

Shanghai Kaibao Pharmaceutical Co's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.958) / 475.497
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Kaibao Pharmaceutical Co  (SZSE:300039) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Shanghai Kaibao Pharmaceutical Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shanghai Kaibao Pharmaceutical Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Business Description

Traded in Other Exchanges
N/A
Address
88 Chengpu Road, Shanghai Industrial Comprehensive Development Zone, Shanghai, CHN, 201401
Shanghai Kaibao Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in research, development, production, and sales of modern Chinese medicine. The company produces traditional Chinese medicines in the form of solid dosage, oral liquids, and small volume injections. Its main product is Tanreqing injection is mainly used for pneumonia, acute and chronic bronchitis and upper respiratory tract infection.
Executives
Liu Shao Yong Supervisors
Ren Li Wang Secretary Dong
Zhang Tao Executives
Mu Jing Wei Director
Li Xiu Hai Directors, executives
Zhang Lian Xin Supervisors
Han Jing Independent director
Wang Guo Ming Directors, executives
Wang Chong Bang Executives
Liu Yi Shan Director
Li Qing Wei Independent director
Mu Lai An Director
Zhu Ying Jun Executives
Chang Qing Ling Supervisors
Zhang Peng Director

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Headlines

No Headlines